Effect of Inferior Alveolar and Gow-Gates Nerve Block Techniques for Symptomatic Mandibular Molars

Symptomatic Irreversible Pulpitis Clinical Trial

Official title:

Effect of Inferior Alveolar and Gow-Gates Nerve Block Techniques for Symptomatic Mandibular Molars

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03117491
• Other study ID #: 395437
• Status: Completed
• Phase: Phase 3
• First received: April 3, 2017
• Last updated: May 4, 2017
• Start date: December 1, 2015
• Est. completion date: December 1, 2016

Study information

• Verified date: April 2017
• Source: Isfahan University of Medical Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Introduction: to evaluate the efficacy of inferior alveolar nerve block (IANB), Gow-Gates nerve block (GGNB), and their combination in patients with irreversible pulpitis. Methods: One hundred fifty subjects with irreversible pulpitis of a mandibular molar were selected. subjects randomly received two IANB injections or two GGNB injections or their combination of 1.8 mL 2% lidocaine with 1:100,000 epinephrine. Success was specified as no or mild pain on the basis of Heft-Parker visual analogue scale recordings up on the access cavity preparation or initial instrumentation. Data were analyzed by Kruskal-Wallis, and ANOVA tests.

Description:

Introduction: to evaluate the efficacy of inferior alveolar nerve block (IANB), Gow-Gates nerve block (GGNB), and their combination in patients with irreversible pulpitis. Methods: One hundred fifty subjects with irreversible pulpitis of a mandibular molar were selected. subjects randomly received two IANB injections or two GGNB injections or their combination of 1.8 mL 2% lidocaine with 1:100,000 epinephrine. Success was specified as no or mild pain on the basis of Heft-Parker visual analogue scale recordings up on the access cavity preparation or initial instrumentation. Data were analyzed by Kruskal-Wallis, and ANOVA tests.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 150
• Est. completion date: December 1, 2016
• Est. primary completion date: November 1, 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• vital mandibular molar tooth

• diagnosis of symptomatic irreversible pulpitis

Exclusion Criteria:

• younger than 18 years old

• history of significant medical conditions

• allergies to local anesthetics or sulfites

• pregnancy

• taking any medications that might influence anesthetic assessment

• active sites of pathosis in area of injection

• inability to give informed consent

Related Conditions & MeSH terms

• Pulpitis
• Symptomatic Irreversible Pulpitis

Intervention

Procedure:
• GGNB injections
The patients received two GGNB injections of 1.8 mL 2% lidocaine with 1:100,000 epinephrine
• IANB injections
The patients received two IANB injections of 1.8 mL 2% lidocaine with 1:100,000 epinephrine
• GGNB + IANB injections
The patients received one GGNB injection plus one IANB injection of 1.8 mL 2% lidocaine with 1:100,000 epinephrine

Locations

Country	Name	City	State
Iran, Islamic Republic of	Isfahan University of Medical Sciences	Isfahan

Sponsors (1)

Lead Sponsor	Collaborator
Isfahan University of Medical Sciences

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the success rate of GGNB local anesthesia technique based on Heft-Parker visual analog scale		at time of access cavity preparation
Primary	the success rate of IANB local anesthesia technique based on Heft-Parker visual analog scale		at time of access cavity preparation
Primary	the success rate of GGNB + IANB local anesthesia techniques based on Heft-Parker visual analog scale		at time of access cavity preparation
Secondary	initial pain based on Heft-Parker visual analog scale		before treatment